Hyeseon Jeon

Hyeseon Jeon

Auto-generated profile, based on publicly available information

Hyeseon Jeon

College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
HJHye Seon Jeon
Hye Seon Jeon
SLSang Won Lee
Sang Won Lee
WJWoojin Jung
Woojin Jung
HJHeeyoon Jung
Heeyoon Jung
DCDonghoon Choi
Donghoon Choi
Howard LeeHoward Lee
Howard Lee
Recombinant human interleukin‐7 hybrid Fc (rhIL‐7‐hyFc) is a homodimer of rhIL‐7 fused to a hyFc. Exogenous IL‐7 promotes T cell proliferation and increases lymphocyte count, making it a potential treatment option for lymphopenia and cancer. To improve therapeutic efficacy, rhIL‐7‐hyFc was developed as a long‐acting IL‐7. This study aimed to create a pharmacokinetic model for rhIL‐7‐hyFc by incorporating neonatal Fc receptor (FcRn)‐mediated recycling and target‐mediated drug disposition (TMDD) of the IL‐7 receptor. Data were collected from a randomized, double‐blind, placebo‐controlled phase 1 trial involving 30 healthy volunteers who received single doses of rhIL‐7‐hyFc. Volunteers received 20 or 60 mg/kg subcutaneously, 60 mg/kg intramuscularly (IM), or a placebo. Clinical data were provided by Genexine Inc. (Seoul, Republic of Korea). A TMDD‐FcRn–mediated recycling pharmacokinetic model was developed using NONMEM 7.5 software, assisted by PsN 5.3.1 software. A quasi‐steady‐state approximation was used to describe drug‐receptor and drug‐FcRn interactions. The model evaluation included goodness of fit, visual predictive checks, and bootstrap analysis. Based on the pharmacokinetic parameters of the final model, a simulation was conducted to select the dosage regimen, ensuring a probability of at least 0.8 for meeting both safety and efficacy criteria. The model successfully described the pharmacokinetic profiles of 24 patients administered rhIL‐7‐hyFc. Based on the simulation results, 670–800 μg/kg every 3 weeks, 1010–1530 μg/kg every 6 weeks, and 1510–2190 μg/kg every 9 weeks IM were proposed. These results may help further understand rhIL‐7‐hyFc characteristics and, moreover, provide guidance for selecting the appropriate dosing regimen in future clinical trials.

15 January 2026 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
WJWoojin Jung
Woojin Jung
JLJaeyeon Lee
Jaeyeon Lee
HJHyeseon Jeon
Hyeseon Jeon
TSTaewook Sung
Taewook Sung
HYHwi-yeol Yun
Hwi-yeol Yun
Jung-woo ChaeJung-woo Chae
Jung-woo Chae
Potassium‐competitive acid blockers (PCABs) are emerging alternatives to proton pump inhibitors for the treatment of acid‐related diseases. However, due to the complex, nonlinear interaction between drug exposure, food intake, and physiological rhythms, optimizing dosing strategies remains challenging. A multi‐leveled population analysis was conducted using published pharmacokinetic and pharmacodynamic data on four representative PCABs: tegoprazan, YH4808, fexuprazan, and vonoprazan. A semi‐mechanistic population PK/PD model was developed to account for food effects, circadian pH rhythms, and pH‐dependent drug absorption. A multi‐level nonlinear mixed‐effects modeling framework was implemented to capture both inter‐drug and inter‐study variability. The model successfully described the time course of plasma concentration and intragastric pH for all four PCABs under various conditions. The model identified differences in pharmacokinetics and pharmacodynamic potency between drugs (with the relative in vitro potency ranked as vonoprazan > fexuprazan > YH4808 > tegoprazan), and simulations demonstrated that both pre‐ and post‐meal administration enhanced pH control in early time period via potentially distinct mechanisms: the pre‐meal effect may arise from temporally separated contributions of food‐ and drug‐induced pH elevation, whereas the post‐meal effect is likely driven by temporally overlapping, additive actions, particularly under low‐dose or non‐steady‐state conditions. Predicted pH profiles and holding times above pH 4 closely matched reported clinical outcomes. The study demonstrates the application of a mechanistic, multi‐level population approach for cross‐drug PK/PD evaluation of PCABs. The findings support drug‐specific dose optimization and highlight the clinical relevance of food–drug interactions. The modeling approach provides a model platform for pharmacotherapy or model‐informed drug development (MIDD).

22 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
HJHyeseon Jeon
Hyeseon Jeon
WJWoojin Jung
Woojin Jung
HYHwi-yeol Yun
Hwi-yeol Yun
SLSoyoung Lee
Soyoung Lee
JKJae Kyoung Kim
Jae Kyoung Kim
JBjong hyuk byun
jong hyuk byun
Target-mediated drug disposition (TMDD) models have been widely used to describe nonlinear pharmacokinetic profiles driven by high-affinity, low-capacity drug–target binding. A pTMDD model, derived by applying the Padé approximation of the quasi-steady-state (QSS) model (qTMDD) was previously proposed. Although pTMDD model showed a comparable estimation accuracy while maintaining computational efficiency, further validation in realistic clinical scenarios and comprehensive performance evaluations have been needed to assess its practical applicability. Here, we evaluated the pTMDD model using five clinical datasets and extended the previous study that focused on simulations. Using the full TMDD as a reference, the approximation models were compared in terms of the parameter estimation results (parameter estimates, relative standard error values and model diagnostics) and computational efficiency (estimation and bootstrap runtimes). The pTMDD model, previously validated in simulation settings, also preserved the estimation accuracy while reducing the computation time of the clinical data. Both pTMDD and qTMDD remained close to the full TMDD model, whereas Michaelis-Menten TMDD (mTMDD) model showed substantial discrepancies especially at low doses, including biased estimates for key TMDD-related parameters (e.g., k deg , k int , k rec , and k up ) and higher objective function values. Moreover, pTMDD was faster than qTMDD in four of the five cases compared to the full TMDD. The time savings were particularly pronounced for larger datasets, supporting the computational efficiency of pTMDD. Q2PCONV, an R Shiny application that converts NONMEM code from qTMDD to pTMDD, was also developed, thereby making this new approximation more accessible to researchers. The findings support pTMDD as a practical alternative to existing TMDD approximation models. Author Summary: Target-mediated drug disposition (TMDD) models describe a high-affinity, low-capacity binding between drug and its target. To avoid overparameterization, approximation models have been used. The two primary models are Michaelis-Menten model (mTMDD), which is accurate only at high doses, and Quasi-steady-state (qTMDD), which is accurate in wider ranges but requires longer runtime. We have proposed a new approximation model named pTMDD. Here, we evaluated pTMDD using five real clinical trial datasets to assess its practical usefulness. pTMDD produced parameter estimates closer to those from the full TMDD model and showed lower uncertainty than both the full TMDD and mTMDD models. In terms of computational efficiency, pTMDD reduced estimation time by an average of 11% and bootstrap time by an average of 6% relative to qTMDD across cases. In addition, we also developed an R shiny application to help researchers apply pTMDD in practice. Our work supports pTMDD as a practical and efficient tool for TMDD modeling in drug development.